XML 45 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
Between 2020 and 2022, we significantly grew our value-based specialty care business, both organically and through acquisitions. Prior to the quarter ended March 31, 2023, the Company was organized under two operating segments and two reportable segments known as Evolent Health Services and Clinical Solutions. At that time, Clinical Solutions was composed of our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health ("NCH") and Evolent Care Partners brands; and Evolent Health Services was composed of our administrative simplification solution and certain supporting population health infrastructure. Our acquisitions of Implantable Provider Group Inc. (August 2022) and National Imaging Associates, Inc. (January 2023) provided additional specialty care management services and cross-sell opportunities covering both technology enabled care management and value-based health plan administrative services within our customer base. The Company is now providing a broad spectrum of specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market strategy, "One Evolent." As such, effective during the three months ended March 31, 2023, the Company changed its reportable segments to reflect changes in the way our CODM evaluates the performance of its operations, develops strategy and allocates capital resources. Specifically, the Company collapsed its previous two reportable segments into one reportable segment. We have one operating segment and one reportable segment as our CODM, reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources.

The transition to “One Evolent” did not change our CODM. We consider our Chief Executive Officer our CODM. The performance measure closest to U.S. GAAP used by our CODM is net loss attributable to common shareholders of Evolent Health, Inc. The CODM uses net loss available to common shareholders of Evolent Health, Inc. to evaluate the performance of the Company’s ongoing operations on a consolidated basis and as part of the Company’s internal planning and forecasting activities. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements.

The following table presents our revenue, significant expenses reviewed by our CODM and net loss attributable to common shareholders of Evolent Health Inc. (in thousands):
For the Year Ended December 31,
202420232022
Revenue$2,554,741$1,963,896$1,352,013
Less:
Medical expense and device costs1,813,052 1,143,499 725,036 
Cost of revenue excluding medical expense and device costs and other segment items (1)
369,754 358,265 304,326 
Selling, general and administrative expenses excluding other segment items (2)
211,475 267,454 216,320 
Depreciation and amortization expenses118,370 123,415 67,195 
Interest income(5,544)(5,256)(1,369)
Interest expense24,722 54,205 15,572 
(Gain) loss from equity method investees3,441 (1,290)(4,569)
Benefit from income taxes(1,413)(89,365)(43,376)
Change in tax receivables agreement liability173 61,982 45,950 
Other segment items (3)
114,165 193,247 46,092 
Net loss attributable to common shareholders of Evolent Health, Inc.$(93,454)$(142,260)$(19,164)
————————
(1)Other segment items excluded from cost of revenue excluding medical expense and device costs include $4.6 million, $1.7 million and $4.4 million of stock compensation for the years ended December 31, 2024, 2023 and 2022, respectively, and $1.6 million of acquisition-related costs and $0.1 million of amortization of contract cost assets for the year ended December 31, 2022.
(2)Other segment items excluded from selling, general and administrative expenses includes $35.2 million, $38.8 million and $29.6 million of stock compensation, $2.9 million, $1.5 million and $13.3 million of severance costs, $2.9 million, $15.1 million and $10.1 million of acquisition-related costs and $10.6 million, $35.2 million and $— million of repositioning costs for the years ended December 31, 2024, 2023 and 2022, respectively.
(3)Other segment items are defined as stock-based compensation, severance costs, acquisition-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses and income (expense) calculated in accordance with GAAP including loss on disposal of non-strategic assets, right-of-use assets impairment, loss on lease termination, change in fair value of contingent consideration, loss on extinguishment/repayment of long-term debt, net, other income (expense), net, loss from discontinued operations, net of tax and loss before preferred dividends and accretion of Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.